Alkem Laboratories Limited
Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)
What Alkem files
- Others96
- Investor Meet62
- Updates42
- Important22
- Board Meeting11
- PPTs11
Alkem Laboratories' board approved Q1FY27 consolidated financial results. Revenue from operations hit ₹3,740.15 Cr, with net profit at ₹519.96 Cr (EPS ₹43.49). Post-quarter, the company acquired a majority stake in Occlutech Holding AG, Switzerland.
Alkem Laboratories' board approved strong FY26 consolidated results: Revenue at ₹14,712.27 Cr & Net Profit at ₹2,301.8 Cr. They also declared a final dividend of ₹10/share (total ₹53/share for FY26) and re-approved Mrs. Madhurima Singh as Executive Director.
Alkem Labs' Board approved Q3 & 9M consolidated results. Q3 revenue grew 11% YoY to ₹3,736.8 Cr, with Net Profit at ₹636 Cr. Declared interim dividend of ₹43/share. Also acquiring majority stake in medical device firm Occlutech.
Alkem Labs' Q2 FY26 consolidated revenue surged 17.2% YoY to ₹4,001 Cr. EBITDA grew 22.3% to ₹920.8 Cr (23% margin), with net profit up 11.1% to ₹765.1 Cr. Strong growth across India & international markets. #Alkem #Earnings
ALKEM's board approved consolidated financial results: Q2 revenue ₹4,001 Cr (profit ₹765 Cr), H1 revenue ₹7,372 Cr (profit ₹1,429 Cr). Results include a ₹14.3 Cr exceptional gain from an Indore facility sale.